GSK’s malaria vaccine phase 3 study containing Agenus’ QS-21 published in The Lancet
Agenus announced final results from a large-scale Phase 3 study of GSK’s malaria vaccine candidate, RTS,S, were published in The Lancet. The study demonstrated a statistically significant reduction against malaria in children who received RTS,S followed by a booster shot of the vaccine at 18 months. April 24, 2015